Diamyd Medical subscribes for an additional SEK 1 million in NextCell Pharma’s ongoing new issue ahead of IPO

Diamyd Medical announces today that the Company will subscribe for an additional SEK 1 million in the ongoing new issue in the associated company NextCell Pharma AB (NCP) ahead of their planned IPO in July on Aktietorget."A listing of NextCell Pharma is clearly positive for Diamyd Medical as it provides a transparent value of our holdings and better risk diversification, while giving NCP greater opportunities to drive its research and business development," says Ulf Hannelius, CEO of Diamyd Medical. NextCell Pharma develops advanced cell therapies with own and donated stem cells. The